The years of political action campaigning finally pay off in a big way. With the help of Senators Reid and Adams, and the testimony of Judith Heller, the Senate Report earmarks $2,500,000 exclusively for IC research and the National Registry.

Baker Norton Pharmaceuticals begins double-blind clinical trials of Nalmefene. Elmiron trials are completed.

The ICA strengthens its relationship with the American Urological Association (AUA) and maintains a booth at the AUA's annual conference in New Orleans.

The ICA is invited to have a representative on the AUA's Bladder Health Council.

Valuable information on IC is made available when the books Overcoming Bladder Disorders and Interstitial Cystitis are published. IC and the ICA appear in a feature article in Health magazine.

The NIH funds an IC research program at Scripps Clinic in La Jolla, California.

NIDDK Urology Director, Dr. Leroy Nyberg, Jr., joins the ICA's Medical Advisory Board as a consultant on NIDDK matters.

The Fifth National Meeting in New Orleans is an unparalleled success.